Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridization

International Journal of Oncology

Volumn 34, Issue 4, 2009, Pages 963-970

  Chan, Michael W Y ^c   Hui, Angela Bik Yu ^a   Yip, Sidney Kam Hung ^b   Ng, Chi Fai ^b   Lo, Kwok Wai ^a   Tong, Joanna H M ^a   Chan, Anthony W H ^a   Cheung, Ho Y ^b   Wong, Wai S ^b   Chan, Peter S F ^b   Lai, Fernand M M ^a   To, Ka Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Allelotyping; Bladder cancer; Comparative genomic hybridization

Indexed keywords

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; AUTOSOME; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 15Q; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 19P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 4Q; CHROMOSOME 8P; CHROMOSOME 9Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE LOSS; GENETIC GAIN; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALLELIC IMBALANCE; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; URINARY BLADDER NEOPLASMS;

EID: 67649421091     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000222     Document Type: Article

References (57)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. Pisani P, Parkin DM and Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55: 891-903, 1993.
3. Knowles MA: What we could do now: molecular pathology of bladder cancer. Mol Pathol 54: 215-221, 2001.
4. Landman L and Droller MJ: Risk factors in clonal development from superficial to invasive bladder cancer. Cancer Surv 31: 5-15, 1998.
5. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD and Hawkins IR: Superficial bladder cancer: progression and recurrence. J Urol 130: 1083-1086, 1983.
6. Weinberg RA: Oncogenes and tumor suppressor genes. CA Cancer J Clin 44: 160-170, 1994.
7. Babu VR, Lutz MD, Miles BJ, Farah RN, Weiss L and Van Dyke DL: Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res 47: 6800-6805, 1987.
8. Cordon-Cardo C: Molecular alterations in bladder cancer. Cancer Surv 32: 115-131, 1998.
9. Gibas Z, Prout GR Jr, Connolly JG, Pontes JE and Sandberg AA: Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 44: 1257-1264, 1984.
10. Vanni R, Scarpa RM, Nieddu M and Usai E: Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenet 30: 35-42, 1988.
11. Dalbagni G, Presti JC Jr, Reuter VE, Zhang ZF, Sarkis AS, Fair WR and Cordon-Cardo C: Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 2: 4-13, 1993.
12. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG: Allelotype of human bladder cancer. Cancer Res 54: 531-538, 1994.
13. Bernues M, Casadevall C, Caballin MR, Miro R, Ejarque MJ, Chechile G, Gelabert A and Egozcue J: Study of allelic losses on 3p, 6q, and 17p in human urothelial cancer. Cancer Genet Cytogenet 112: 42-45, 1999.
14. Choi C, Kim MH, Juhng SW and Oh BR: Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder. Int J Cancer 86: 501-505, 2000.
15. Zhang J, Zheng S, Gao Y, Rotolo JA, Xiao Z, Li C and Cheng S: A partial allelotyping of urothelial carcinoma of bladder in the Chinese. Carcinogenesis 25: 343-347, 2004.
16. Bartoletti R, Cai T, Nesi G, Roberta Girardi L, Baroni G and Dal Canto M: Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res 143: 422-427, 2007.
17. Sourvinos G, Kazanis I, Delakas D, Cranidis A and Spandidos DA: Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes. J Urol 165: 249-252, 2001.
18. Hovey RM, Chu L, Balazs M, DeVries S, Moore D, Sauter G, Carroll PR and Waldman FM: Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58: 3555-3560, 1998.
19. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ and Sauter G: Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 153: 1615-1621, 1998.
20. Prat E, Bernues M, Caballin MR, Egozcue J, Gelabert A and Miro R: Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology 57: 986-992, 2001.
21. Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B, Tse GM, Ding M, Li X, Lee JC and Huang DP: High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 60: 5365-5370, 2000.
22. Hui AB, Lo KW, Leung SF, Teo P, Fung MK, To KF, Wong N, Choi PH, Lee JC and Huang DP: Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 82: 498-503, 1999.
23. Hsu LI, Chiu AW, Pu YS, Wang YH, Huan SK, Hsiao CH, Hsieh FI and Chen CJ: Comparative genomic hybridization study of arsenic-exposed and non-arsenic-exposed urinary transitional cell carcinoma. Toxicol Appl Pharmacol 227: 229-238, 2008.
24. Qin SL, Chen XJ, Xu X, Shou JZ, Bi XG, Ji L, Han YL, Cai Y, Wei F, Ma JH, Wu M, Zhan QM and Wang MR: Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization. Cancer Lett 238: 230-239, 2006.
25. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP and Waldman FM: Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11: 7012-7022, 2005.
26. Li M, Zhang ZF, Reuter VE and Cordon-Cardo C: Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 149: 229-235, 1996.
27. Dalbagni G, Presti J, Reuter V, Fair WR and Cordon-Cardo C: Genetic alterations in bladder cancer. Lancet 342: 469-471, 1993.
28. Kallioniemi A, Kallioniemi OP, Citro G, Sauter G, DeVries S, Kerschmann R, Caroll P and Waldman F: Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 12: 213-219, 1995.
29. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP and Knowles MA: High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 23: 2250-2263, 2004.
30. Lopez-Beltran A, Alvarez-Kindelan J, Luque R, Blanca A, Quintero A, Montironi R, Cheng L, Gonzalez-Campora R and Requena M: Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol 215: 263-272, 2008.
31. Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM and To KF: Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 104: 611-616, 2003.
32. Muscheck M, Sukosd F, Pesti T and Kovacs G: High density deletion mapping of bladder cancer localizes the putative tumor suppressor gene between loci D8S504 and D8S264 at chromosome 8p23.3. Lab Invest 80: 1089-1093, 2000.
33. Ohgaki K, Iida A, Ogawa O, Kubota Y, Akimoto M and Emi M: Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22. Genes Chromosomes Cancer 25: 1-5, 1999.
34. Yin XL, Pang JC and Ng HK: Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma. Oncogene 21: 1461-1468, 2002.
35. Arbieva ZH, Banerjee K, Kim SY, Edassery SL, Maniatis VS, Horrigan SK and Westbrook CA: High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22. Genome Res 10: 244-257, 2000.
36. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, et al: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869-3873, 1993.
37. Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC and Chinault AC: Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene 20: 4169-4179, 2001.
38. Toyooka S, Fukuyama Y, Wistuba, II, Tockman MS, Minna JD and Gazdar AF: Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 8: 2292-2297, 2002.
39. Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM and Baffa R: FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 160: 1345-1352, 2002.
40. Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM and Baffa R: Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res 7: 1546-1552, 2001.
41. Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R and Croce CM: FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci USA 98: 10374-10379, 2001.
42. Balazs M, Carroll P, Kerschmann R, Sauter G and Waldman FM: Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 19: 84-89, 1997.
43. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D and Cordon-Cardo C: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87: 1524-1529, 1995.
44. Packenham JP, Taylor JA, Anna CH, White CM and Devereux TR: Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinog 14: 147-151, 1995.
45. Southgate J, Proffitt J, Roberts P, Smith B and Selby P: Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br J Cancer 72: 1214-1218, 1995.
46. Stadler WM and Olopade OI: The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24: 239-244, 1996.
47. Habuchi T, Devlin J, Elder PA and Knowles MA: Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 11: 1671-1674, 1995.
48. Habuchi T, Yoshida O and Knowles MA: A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Hum Mol Genet 6: 913-919, 1997.
49. Keen AJ and Knowles MA: Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9: 2083-2088, 1994.
50. Nishiyama H, Takahashi T, Kakehi Y, Habuchi T and Knowles MA: Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer 26: 171-175, 1999.
51. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM and To KF: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8: 464-470, 2002.
52. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S and Kuwano M: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62: 4048-4053, 2002.
53. Habuchi T, Luscombe M, Elder PA and Knowles MA: Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48: 277-288, 1998.
54. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM and Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53: 3241-3245, 1993.
55. Nakopoulou L, Zervas A, Gakiopoulou-Givalou H, Constantinides C, Doumanis G, Davaris P and Dimopoulos C: Prognostic value of E-cadherin, beta-catenin, P120ctn in patients with transitional cell bladder cancer. Anticancer Res 20: 4571-4578, 2000.
56. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der Maase H and Orntoft TF: High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 65: 34-45, 2005.
57. Hoque MO, Lee CC, Cairns P, Schoenberg M and Sidransky D: Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 63: 2216-2222, 2003.